Industry Spotlight: Yamo Pharmaceuticals
About Yamo Pharmaceuticals
Yamo Pharmaceuticals is a clinical-stage company dedicated to developing L1-79, an oral treatment targeting core social-interaction deficits in individuals with Autism Spectrum Disorder (ASD). In 2017 the company completed a randomized, double-blind, placebo-controlled 4-week study in 42 male patients aged 13 to 21 years with autism. Based on encouraging results, including positive trends in the Vineland-II Socialization Standard Score, Yamo was granted Fast Track Designation by the FDA in May 2018.
In June 2024 the company completed a Phase 2 clinical trial evaluating L1-79 in adolescents and young adults with ASD. This study demonstrated a favorable safety profile and positive results, including significant improvements in socialization metrics.
L1-79 mechanisms of action include::
- Modulation of catecholamine pathways, which influence critical brain functions such as mood, attention, motor skills, and social behavior;
- Mechanisms in the central nervous system (CNS) which regulate mood, attention, reward, irritability, attention, motor function and other elements in the brain which appear to be affected by autism;
- Different systems in the CNS which serve to modify brain function through inhibition and which are believed to be deficient in the hyperactive CNS state that characterizes autism;
- Mechanisms in the gut which have been hypothesized to play an important role in some forms of autism;
- Mechanisms in the liver and pancreas that are altered in the presence of some individuals with autism, and;
- A novel system of integrated neurologic and metabolic signaling that unites the gut, the mesenteric organs, the central nervous system and the autonomic nervous system.
Visit Yamo website for more information about the company, L1-79, or opportunities to participate in their future clinical studies.